Invex Therapeutics (ASX:IXC) is a biopharmaceutical drug development Company seeking to develop efficacious treatments for neurological conditions resulting from raised intracranial pressure (ICP). ICP is a serious issue in a range of neurological conditions, including idiopathic intracranial hypertension, traumatic brain injury or acute stroke.

Invex is focused on research and development centered around understanding and defining the mechanisms that regulate pressure in the brain and in particular the repurposing of an already approved drug, Exenatide, to reduce ICP and address a significant unmet medical need. Invex has trademarked its repurposed Exenatide as Presendin™.